Qiagen wins FDA clearance for first QIAstat-Dx bloodstream infection panel

• Qiagen won U.S. FDA clearance for its first QIAstat-Dx bloodstream infection test, the BCID GPF Plus AMR Panel.
• Panel identifies gram-positive bacterial or fungal targets, a pan gram-negative target, antimicrobial resistance markers from positive blood cultures in about one hour.
• Clearance expands the QIAstat-Dx U.S. menu into bloodstream infections; a gram-negative BCID GN Plus AMR Panel remains under FDA review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief via Business Wire (Ref. ID: 20260810720979) on August 10, 2026, and is solely responsible for the information contained therein.